- Home
- URG vs DCTH Comparison
URG vs DCTH Comparison
Compare URG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URG
- DCTH
- Stock Information
- Founded
- URG 2004
- DCTH 1988
- Country
- URG United States
- DCTH United States
- Employees
- URG N/A
- DCTH N/A
- Industry
- URG Precious Metals
- DCTH Medical/Dental Instruments
- Sector
- URG Basic Materials
- DCTH Health Care
- Exchange
- URG Nasdaq
- DCTH Nasdaq
- Market Cap
- URG 419.5M
- DCTH 394.9M
- IPO Year
- URG N/A
- DCTH N/A
- Fundamental
- Price
- URG $1.18
- DCTH $10.36
- Analyst Decision
- URG Strong Buy
- DCTH Strong Buy
- Analyst Count
- URG 3
- DCTH 4
- Target Price
- URG $2.63
- DCTH $24.50
- AVG Volume (30 Days)
- URG 4.0M
- DCTH 838.4K
- Earning Date
- URG 08-05-2025
- DCTH 08-06-2025
- Dividend Yield
- URG N/A
- DCTH N/A
- EPS Growth
- URG N/A
- DCTH N/A
- EPS
- URG N/A
- DCTH 0.06
- Revenue
- URG $39,488,000.00
- DCTH $70,240,000.00
- Revenue This Year
- URG N/A
- DCTH $160.46
- Revenue Next Year
- URG $224.22
- DCTH $42.87
- P/E Ratio
- URG N/A
- DCTH $185.17
- Revenue Growth
- URG 149.20
- DCTH 491.35
- 52 Week Low
- URG $0.55
- DCTH $7.36
- 52 Week High
- URG $1.42
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- URG 45.88
- DCTH 39.80
- Support Level
- URG $1.15
- DCTH $9.87
- Resistance Level
- URG $1.29
- DCTH $11.21
- Average True Range (ATR)
- URG 0.07
- DCTH 0.76
- MACD
- URG -0.02
- DCTH 0.09
- Stochastic Oscillator
- URG 17.86
- DCTH 13.73
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.